$CSDX - "has been featured by @ts_reports for our CS-Protect Hydrogel, now on the fast track to FDA approval. This next-gen innovation in radiation therapy positions CS Diagnostics Corp. as a standout player in cancer radiology offering transformative potential for patient care. Upon FDA clearance, production is slated to commence in early 2026 bringing the product to patients across the U.S. A safer solution for cancer care starts now! Read more: